Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, April 26, 2013 Dyax Corp (NASDAQ:DYAX), Down By 7.82% ($0.33) From $4.220 After BUYINS.NET Report Predicted Weakness After Earnings
April 26, 2013 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, April 24th 2013 stating that Dyax Corp (NASDAQ:DYAX) was expected to be Down After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=dyax&id=363113
At the time this story was written, Dyax Corp (NASDAQ:DYAX) is Down By 7.82% ($0.33) From $4.220 since the BUYINS.NET report was released.
The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php
Dyax Corp (NASDAQ:DYAX) - Dyax Corp., a biopharmaceutical company, focuses on identification, development, and commercialization of treatments for conditions identified as plasma kallikrein mediated angioedema. The company develops KALBITOR by using its phage display technology for the treatment of acute attacks of HAE. It markets KALBITOR through wholesale and co-exclusive specialty pharmacy arrangements in the United States. The company is also involved in the clinical development of ecallantide for use in the treatment of ACEI-AE; and development of a human monoclonal antibody inhibitor of plasma kallikrein, which is a candidate to prophylactically treat plasma kallikrein mediated angioedemas. In addition, the company, through licensing and funded research program (LFRP), has 18 product candidates in clinical development. Dyax Corp. grants its licensees the rights to use its phage display libraries in connection with their internal therapeutic development programs; performs funded research for various collaborators using its phase display technology to identify, characterize, and optimize antibodies under the funded research program; and grants other biopharmaceutical and pharmaceutical companies non-exclusive licenses to use its core phage display patents to discover and develop biologic compounds under the patent license program. It has a strategic collaboration agreement with Sigma-Tau Rare Diseases S.A. to develop and commercialize ecallantide for the treatment of HAE and other therapeutic indications in Europe, North Africa, the Middle East, and Russia; and a strategic partnership with the Novellus Biopharma AG for the development and commercialization of KALBITOR for the treatment of hereditary angioedema and other angioedema indications in Latin America, as well as a strategic partnership with CVie Therapeutics for the development and commercialization of KALBITOR in China, Hong Kong, and Macau. The company was founded in 1989 and is headquartered in Burlington, Massachusetts..
About BUYINS.NET
BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.
INVESTMENTS & TRADING
SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.
GATS -- tracks and quantifies known trading strategies.
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Dyax Corp (NASDAQ:DYAX) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net
- WOPRAI
- support@woprai.com